ArticleCrohn's & colitis 3602026

Evaluating the access process for patients transitioning from intravenous to subcutaneous biologic administration for inflammatory bowel disease.

Taylor Kissel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.